

# Biocept Inc

17:10 12 Aug 2019

## Biocept shares rise after reporting revenue boost in 2Q

Biocept Inc (NASDAQ:BIOC) shares climbed in extended trading Monday after reporting a 45% boost in revenue during the second quarter of 2019, compared with the same period a year ago.

The supplier of liquid biopsy tests said it continues to execute on its new commercial strategy and has seen an increase in commercial samples. The San Diego-based company has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA.

Biocept shares were up 6.8% to \$1.09 in Monday's after-hours trading.

**READ:** Major US laboratory network to carry Biocept's flagship liquid biopsy tests

"Growth was driven by a 26% year-over-year increase in commercial samples, as we focused our commercial efforts on segments of the liquid biopsy oncology market where Target Selector can help the most patients, namely in prostate, breast, and lung cancers," said CEO Michael Nall in a statement. "Most importantly, we are helping more patients as our billable samples accessioned per sales day entering the third quarter increased approximately 50% from the beginning of the year."

The firm launched two tumor-specific panels developed in collaboration with Thermo Fisher Scientific: Target Selector NGS Lung Panel and Target Selector NGS Breast Panel, the company's first two multi-gene liquid biopsy panels.

The NGS Panels run on Thermo Fisher Scientific's Ion Torrent NGS platform and are being marketed to physicians and researchers for the detection and monitoring of actionable biomarkers associated with these tumor-specific cancers.

Biocept saw its revenue for the second quarter come in at \$1.2 million, a 45% increase compared to the \$822,000 posted in the same period a year ago.

The firm reported a net loss for 2Q of \$7.8 million, or \$0.38 per share, a narrowing in its loss for the year-ago period of \$6.2 million, or \$2.70 per share. Biocept conducted a 1-for-30 reverse stock split of its outstanding common stock in July 2018.

The company had cash and cash equivalents of \$12.6 million as of June 30, 2019.

Contact Katie Lewis at [katie@proactiveinvestors.com](mailto:katie@proactiveinvestors.com)

**Price:** 0.3257

**Market Cap:** \$13.75 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** BIOC

**Listing:** NASDAQ

52 week	High	Low
	2.25	0.2275

**Sector:** Medical technology & services

**Website:** [biocept.com](http://biocept.com)

### Company Synopsis:

*Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA).*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).